Eptinezumab
Eptinezumab
Eptinezumab (pronounced ep-ti-nez-u-mab) is a monoclonal antibody medication used for the preventive treatment of migraine in adults. It is marketed under the brand name Vyepti.
Etymology
The name "Eptinezumab" is derived from the International Nonproprietary Names (INN) system, which follows a specific pattern for naming monoclonal antibodies. The "-mab" suffix indicates it is a monoclonal antibody, while the "ezu" infix suggests it targets the human nervous system.
Mechanism of Action
Eptinezumab works by binding to the calcitonin gene-related peptide (CGRP) ligand and preventing it from binding to its receptor. CGRP is a neuropeptide that plays a crucial role in the pathophysiology of migraines.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Migraine: A type of headache characterized by recurrent attacks of moderate to severe pain, often on one side of the head, and accompanied by nausea, vomiting, and sensitivity to light and sound.
- CGRP: A neuropeptide that plays a crucial role in the transmission of pain and the resulting inflammatory response.
Side Effects
Common side effects of Eptinezumab include nasal and throat irritation, hypersensitivity reactions, and upper respiratory tract infection.
Administration
Eptinezumab is administered as an intravenous infusion every three months.
See Also
External links
- Medical encyclopedia article on Eptinezumab
- Wikipedia's article - Eptinezumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski